Obigen Pharma Inc. (7876)

Overview

Obigen Pharma Inc. is a biopharmaceutical company headquartered in Zhubei City, Taiwan. Established in 2020, the company is primarily dedicated to the research, development, production, manufacturing, and sale of botulinum toxin products. Operating within the biotechnology sector, Obigen Pharma focuses on biological products, excluding diagnostic substances, and is committed to advancing therapeutic toxins, which have promising applications in the fields of medical aesthetics and various treatments. The company employs approximately 53 people and is positioned as a key player in Taiwan’s growing biotech landscape, contributing significantly to innovative healthcare solutions.

Obigen Pharma's lead product, OBI-858, is a groundbreaking 760 kDa toxin protein that is derived from the fermentation and purification of Clostridium botulinum type A bacteria. Currently undergoing Phase II clinical trials, this product reflects the company's commitment to harnessing the potential of botulinum toxin for therapeutic uses. As a subsidiary of OBI Pharma, Obigen Pharma benefits from strategic collaborations that enhance its capabilities in oncology and drug development, thereby solidifying its standing in a competitive pharmaceuticals and biotech industry.

The leadership team, including CEO Peifen Chou and CFO Sheila Chuang, guides the company with a clear mission to innovate and expand its offerings while contributing to the advancement of biopharmaceutical sciences.

Products and Services

• OBI-858

  OBI-858 is the flagship product of Obigen Pharma, characterized as a novel 760 kDa botulinum toxin protein. It is the result of meticulous research and development processes involving the fermentation and purification of Clostridium botulinum type A bacteria. Currently, OBI-858 is advancing through Phase II clinical trials, indicating significant steps toward potential market introduction. The therapeutic applications of OBI-858 span medical aesthetics, where it may be utilized for cosmetic procedures, as well as various medical conditions requiring muscle relaxation or inhibition of neuromuscular transmission.

• Research and Development

  Obigen Pharma invests heavily in research and development, focusing on the innovative uses of botulinum toxin and other biological products. The R&D team works continuously to explore new methodologies and applications that could lead to various medical and therapeutic breakthroughs. This commitment serves not only to develop current products but also to discover novel treatments that can address unmet medical needs.

• Manufacturing and Quality Control

  The company has established sophisticated manufacturing protocols that comply with industry standards for quality control. The production of its botulinum toxin products is conducted in state-of-the-art facilities designed to ensure the highest levels of safety, efficacy, and quality in the final products. This commitment to stringent manufacturing processes confirms Obigen Pharma's dedication to delivering reliable and effective biopharmaceutical products.